
|Videos|August 26, 2021
Role of First Generation FLT3 Inhibitors in AML
Expert discusses the role of FLT3 inhibitors in the treatment of AML and if benefit from midostaurin in combination with chemotherapy can be predicted.
Advertisement
Episodes in this series

Now Playing
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
3
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
4
Balancing Survival and Quality of Life in Pancreatic Cancer: Expert Perspectives From an Immuneering Panel
5



























